Cargando…
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricula...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154317/ https://www.ncbi.nlm.nih.gov/pubmed/32309534 http://dx.doi.org/10.1016/j.ijcha.2020.100503 |
| _version_ | 1783521801954918400 |
|---|---|
| author | Antunes, Murillo de Oliveira Scudeler, Thiago Luis |
| author_facet | Antunes, Murillo de Oliveira Scudeler, Thiago Luis |
| author_sort | Antunes, Murillo de Oliveira |
| collection | PubMed |
| description | Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients. The goal of pharmacological therapy in HCM is to alleviate the symptoms, and it includes pharmacotherapies and septal reduction therapies. In this review, we summarize the relevant clinical issues and treatment options of HCM. |
| format | Online Article Text |
| id | pubmed-7154317 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71543172020-04-17 Hypertrophic cardiomyopathy Antunes, Murillo de Oliveira Scudeler, Thiago Luis Int J Cardiol Heart Vasc Review Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients. The goal of pharmacological therapy in HCM is to alleviate the symptoms, and it includes pharmacotherapies and septal reduction therapies. In this review, we summarize the relevant clinical issues and treatment options of HCM. Elsevier 2020-03-25 /pmc/articles/PMC7154317/ /pubmed/32309534 http://dx.doi.org/10.1016/j.ijcha.2020.100503 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Review Antunes, Murillo de Oliveira Scudeler, Thiago Luis Hypertrophic cardiomyopathy |
| title | Hypertrophic cardiomyopathy |
| title_full | Hypertrophic cardiomyopathy |
| title_fullStr | Hypertrophic cardiomyopathy |
| title_full_unstemmed | Hypertrophic cardiomyopathy |
| title_short | Hypertrophic cardiomyopathy |
| title_sort | hypertrophic cardiomyopathy |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154317/ https://www.ncbi.nlm.nih.gov/pubmed/32309534 http://dx.doi.org/10.1016/j.ijcha.2020.100503 |
| work_keys_str_mv | AT antunesmurillodeoliveira hypertrophiccardiomyopathy AT scudelerthiagoluis hypertrophiccardiomyopathy |